💼 What the Company Does
Eli Lilly and Company is a global pharmaceutical company that develops, manufactures, and sells medicines for major diseases, including diabetes, obesity, cancer, immunology, and neuroscience disorders.
In FY2025, the company’s business was strongly supported by demand for obesity and diabetes medicines such as Mounjaro and Zepbound. Eli Lilly also continued investing in research, manufacturing capacity, and global product expansion.
📊 Financial Highlights
Eli Lilly’s FY2025 financial results showed a major increase in business scale. Revenue rose to $65,179m, compared with $45,043m in FY2024 and $34,124m in FY2023.
- Operating income increased to $26,302m in FY2025.
- Net income increased to $20,640m.
- Diluted EPS increased to $23.0.
- Operating cash flow rose to $16,813m.
- Operating margin improved to 40.4%.
In plain English, Eli Lilly did not just grow sales. It also converted a much larger portion of its revenue into profit and cash flow.
⚠️ Key Risks
Eli Lilly’s main risks are closely tied to the pharmaceutical industry and the company’s current growth drivers.
- Obesity and diabetes drug concentration: A large part of current growth depends on continued demand for key products such as Mounjaro and Zepbound.
- Clinical trial risk: New medicines may fail during testing or face regulatory delays.
- Drug pricing pressure: Governments, insurers, and healthcare systems may push for lower prices.
- Manufacturing risk: Strong demand requires reliable production capacity and supply-chain execution.
- Patent and competition risk: Successful drugs can eventually face generic, biosimilar, or branded competition.
For beginner investors, the key point is simple: Eli Lilly has strong growth drivers, but those drivers depend on continued product demand, regulatory approvals, manufacturing execution, and protection from competition.
🧭 MD&A
Management emphasized strong FY2025 growth driven mainly by obesity and diabetes medicines. The company also highlighted improved profitability, higher operating cash flow, and continued investment in manufacturing capacity.
Eli Lilly continued spending heavily on R&D, which means research and development for future medicines. Management also discussed global product expansion and the need to support growing demand through larger production capacity.
✅ Takeaway
Eli Lilly’s FY2025 10-K shows a rapidly growing pharmaceutical company with strong revenue growth, sharply higher profitability, and expanding cash flow.
The company’s recent performance was strongly supported by obesity and diabetes medicines, while management continued investing in manufacturing and future drug development.
At the same time, investors should understand that Eli Lilly remains exposed to product concentration, regulation, drug pricing pressure, clinical development uncertainty, and competition.
For beginner investors, Eli Lilly’s 10-K shows a high-growth healthcare company with powerful current products and important industry-specific risks.
Income Statement Summary
| (Unit: $m, EPS in $) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | 34,124 | 45,043 | 65,179 |
| Cost of Goods Sold | 7,082 | 8,418 | 11,052 |
| Gross Profit | 27,042 | 36,625 | 54,127 |
| SG&A | 7,404 | 8,594 | 11,094 |
| Operating Income | 6,457 | 12,899 | 26,302 |
| Non-Operating Income/Expense | 97 | (219) | (571) |
| Interest Income/Expense | — | — | — |
| Income Before Tax | 6,554 | 12,680 | 25,731 |
| Income Tax | 1,314 | 2,090 | 5,091 |
| Net Income | 5,240 | 10,590 | 20,640 |
| EPS | 5.8 | 11.7 | 23.0 |
Plain English: Eli Lilly’s income statement shows a major step-up in scale. Revenue increased from $34,124m in FY2023 to $65,179m in FY2025, while operating income rose much faster, from $6,457m to $26,302m. This means the company was not only selling more, but also converting a much larger share of those sales into operating profit. Net income nearly quadrupled over the three-year period, and diluted EPS increased from $5.8 to $23.0.
Key Financial Ratios
| Ratio | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| ROE (%) | 48.2% | 74.2% | 77.8% |
| ROA (%) | 8.2% | 13.5% | 18.4% |
| ROTC (%) | 17.9% | 26.9% | 38.1% |
| ROIC (%) | 15.5% | 24.1% | 34.2% |
| Gross Margin (%) | 79.2% | 81.3% | 83.0% |
| Operating Margin (%) | 18.9% | 28.6% | 40.4% |
| Pretax Margin (%) | 19.2% | 28.2% | 39.5% |
| Net Margin (%) | 15.4% | 23.5% | 31.7% |
| Debt-to-Equity Ratio (D/E) (%) | 232.2% | 235.7% | 160.2% |
| Net Debt / EBITDA (x) | 2.8x | 2.1x | 1.2x |
| Interest Coverage Ratio (x) | — | — | — |
| Current Ratio (%) | 94.3% | 115.4% | 157.9% |
| Quick Ratio (%) | 51.9% | 58.3% | 77.8% |
| Fixed Asset to Long-term Capital Ratio (%) | 44.2% | 40.0% | 36.6% |
Plain English: The ratio table shows a sharp improvement in profitability and capital efficiency. Gross margin rose to 83.0%, operating margin reached 40.4%, and ROIC improved to 34.2% in FY2025. For beginners, ROIC means how efficiently a company turns invested capital into operating profit after tax. Eli Lilly also improved its leverage profile: Net Debt / EBITDA fell from 2.8x in FY2023 to 1.2x in FY2025, meaning earnings power grew faster than net debt.
📝 Disclaimer
This article is intended for educational purposes only. It does not constitute financial, investment, or legal advice. All investment decisions involve risks, and readers should conduct their own research or consult with a licensed financial advisor.
👉 Eli Lilly and Company (LLY) FY 2025 10-K Analysis (Filed 2026) | Explained for Beginners
Originally published on Finvincio